Today marks a significant milestone in my life as I bid farewell to MD Anderson Cancer Center after 15 years of unwavering dedication. Leaving with a profound sense of fulfillment, pride, and humility, I am immensely grateful for the collaborative efforts that have led to numerous FDA and EMA approvals, benefiting individuals with cancer not only in the United States but also worldwide. As I embark on this new journey, I am filled with excitement and anticipation for what lies ahead. Joining the exceptional team at Sarah Cannon on June 1, I am thrilled to contribute to our shared mission of bringing cutting-edge clinical trials directly to patients, wherever they may be. Let us forge ahead and continue making a transformative impact in the battle against cancer.
